Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 October 2020 | Story Lacea Loader

The Free State is currently one of the provinces in the country with the highest percentage of new tests that turn out positive for COVID-19. This also impacts on the staff and students at the University of the Free State (UFS), as the number of positive cases on the campuses has increased considerably during the past few weeks.  

The UFS experienced an increase of 47% in the number of students who tested positive from Level 2 of the national lockdown to Level 1. During the past few days, an increase of 21% in positive student cases has been experienced. In the case of staff, an increase of 34% in the number who tested positive occurred from Level 2 of the national lockdown to Level 1. Over  the past few days, an increase of 11% in positive cases has been experienced.

1. Adherence to national protocols and regulations

The safety, health, and well-being of staff and students remain a priority. Therefore, the university management is concerned about the rise in positive cases on the campuses and appeals to staff to adhere to the national protocols and regulations issued by the Ministers of Cooperative Governance and Traditional Affairs, Employment and Labour, Higher Education, Science and Innovation, and Health.   

It is important to note that non-adherence to certain of the national protocols and regulations is a criminal offence and is punishable by a fine or imprisonment of up to six months. By not adhering to national protocols and regulations, our staff is not only putting their own health at risk, but also the health of others.

2. Behaviour observed on campus  

The following behaviour has been observed among staff working on campus:
- Not adhering to social/physical distancing of 2 metres;
- Face-to-face contact without wearing masks (e.g. in boardrooms and tearooms, visiting each other in offices, etc);
- Not wearing a mask while moving on campus, as well as in buildings (except in the privacy of offices);
- Dishonesty during the screening process; and
- Non-compliance with isolation and quarantine guidelines.
Staff members are reminded that they may face disciplinary action if they do not adhere to the national COVID-19 protocols and regulations as issued by the different ministers. It is important that staff members be honest at all times during the screening process, as it has been observed that some staff members display some COVID-19-related symptoms but answer in the negative on the online screening app.

3. Reporting of positive COVID-19 cases
In terms of the directives issued by the Minister of Employment and Labour, the Minister of Health, and the Minister of Higher Education, Science and Innovation, the UFS is required to report all COVID-19 positive cases to the Department of Labour, the Department of Health, and the Department of Higher Education and Training.  All COVID-19 positive cases must thus be reported directly to the Senior Director: Human Resources (vjaarsj@ufs.ac.za) and Kovsie Health (johnr@ufs.ac.za) for further handling and reporting to the relevant government departments.

Please do not come to the campuses if you are experiencing any COVID-19-related symptoms and get tested as soon as possible.

Those staff members who test positive will receive the necessary advice from their medical practitioners and they can also contact Kovsie Health for assistance.


News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept